Clinical Validation of Immunovia Next-Generation Blood Biomarker Test to Detect Early-Stage Pancreatic Cancer

CompletedOBSERVATIONAL
Enrollment

1,066

Participants

Timeline

Start Date

September 2, 2024

Primary Completion Date

December 9, 2024

Study Completion Date

January 6, 2025

Conditions
Pancreatic Cancer Stage IPancreatic Cancer Stage IICancer DiagnosisPDAC - Pancreatic Ductal Adenocarcinoma
Trial Locations (15)

22031

Inova Schar Cancer Institute, Fairfax

23284

Virginia Commonwealth University, Richmond

33136

University of Miami, Miami

38103

Regional One Health, Memphis

60637

University of Chicago Medical Center, Chicago

85258

HonorHealth Clinical Research Institute, Scottsdale

91505

St. John's Cancer Institute, Burbank

92093

University of California San Diego, La Jolla

94305

Stanford Gastroenterology and Hepatology, Stanford

97239

Oregon Health Sciences University, Portland

10029-6574

Mount Sinai Hospital, New York

15213-2582

University of Pittsburgh Medical Center, Pittsburgh

Unknown

The Research Institute of the McGill University Health Centre, Montreal

University of Verona, Verona

Oslo University Hospital, Oslo

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Immunovia, Inc.

INDUSTRY